Colombia’s Consejo de Estado has upheld an order requiring the government to lay the foundations of a new national pharmaceutical policy, with potential consequences for drug pricing, supply, and local …
Colombia’s Consejo de Estado has upheld an order requiring the government to lay the foundations of a new national pharmaceutical policy, with potential consequences for drug pricing, supply, and local …
The head of Buenos Aires’ Institute for Clinical Effectiveness and Health Policy says a national agency should give Argentina a common evidence base, not centralize every decision, and that coverage …
Chile’s former top drug regulator says faster approvals mean little if coverage stalls, and wants the medicines agency separated administratively from the Institute of Public Health.
Chile’s 2027 budget bill trims the Ley Ricarte Soto line to CLP 166,951m while health spending rises 4.7% in real terms, signalling little room for new high-cost therapies.
A bill backed by Peru’s health ministry would make clinics calculate drug copayments from Digemid market prices, not the Kairos catalogue. If it passes, expect clinics to seek the margin …
Zymeworks completes its $929 million acquisition of Theravance Biopharma, adding a 35% US profit share in revefenacin (Yupelri) and a 20% share of any future ampreloxetine deal to its royalty-driven …
A committee of Conitec, Brazil’s health technology assessment body, provisionally recommended ViiV’s HIV-prevention injection at its proposed price of about R$6,660 a year, while Brazil offered Gilead roughly a third …
Two Medtronic cardiac devices had ANVISA registrations published on September 21, 2026, about 35 and 17 months after FDA approval, while BAGUERA C, Belotero and SELUTION SLR were registered in …
Afya and Yduqs signed a merger agreement on September 23, 2026, creating a combined group with R$9.4 billion in revenue and roughly 5,900 annual medical-school seats, subject to antitrust review …
Peru’s Digemid has approved South Korean regenerative medicine company L&C Bio’s Re2O, an injectable based on human skin extracellular matrix, for commercialisation; the company plans to use Peru as a …
You must be logged in to post a comment.